T cell immunity to measles viral proteins in infants and adults after measles immunization

Viral Immunology

Volumn 17, Issue 2, 2004, Pages 298-307

  Gans, Hayley A ^a   Yasukawa, Linda L ^a   Alderson, Amanda ^a   Rinki, Mary ^a   Dehovitz, Ross ^b   Maldonado, Yvonne ^a   Arvin, Ann M ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b PALO ALTO MEDICAL FOUNDATION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGEN; CD8 ANTIGEN; HLA A2 ANTIGEN; HYBRID PROTEIN; MEASLES MUMPS RUBELLA VACCINE; MEASLES VACCINE; SYNTHETIC PEPTIDE; VIRUS PROTEIN;

ANTIBODY RESPONSE; ANTIGEN SPECIFICITY; ARTICLE; CELL PROLIFERATION; CELLULAR IMMUNITY; FEMALE; HUMAN; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNOGENICITY; INFANT; MAJOR CLINICAL STUDY; MALE; MEASLES; MEASLES VIRUS; T LYMPHOCYTE ACTIVATION; VACCINATION; VIRUS NUCLEOCAPSID;

ADULT; ANTIBODIES, VIRAL; ANTIGENS, VIRAL; CD8-POSITIVE T-LYMPHOCYTES; HUMANS; INFANT; INFANT, NEWBORN; LYMPHOCYTE ACTIVATION; MEASLES VACCINE; PEPTIDES; T-LYMPHOCYTES; VACCINES, ATTENUATED;

MEASLES VIRUS; RNA VIRUSES;

EID: 3042772399     PISSN: 08828245     EISSN: None     Source Type: Journal    
DOI: 10.1089/0882824041310522     Document Type: Article

References (38)

1. Aaby, P., M. Andersen, and K. Knudsen. 1993. Excess mortality after early exposure to measles. Int. J. Epidemiol. 22:156.
2. Aaby, P., J. Bukh, D. Kronborg, et al. 1990. Delayed excess mortality after exposure to measles during the first six months of life. Am. J. Epidemiol. 132:211.
3. Albrecht, P., F.A. Ennis, E.J. Saltzman, et al. 1977. Persistence of maternal antibody in infants beyond 12 months: mechanism of measles vaccine failure. J. Pediatr. 91:715.
4. Asanuma, H., M. Sharp, H.T. Maecker, et al. 2000. Frequencies of memory T cells specific for varicella-zoster virus, herpes simplex virus, and cytomegalovirus by intracellular detection of cytokine expression. J. Infect. Dis. 181:859.
5. Barrios, C., P. Brawand, M. Berney, et al. 1996. Neonatal and early life immune responses to various forms of vaccine antigens qualitatively differ from adult responses: predominance of a Th2-biased pattern which persists after adult boosting. Eur. J. Immunol. 26:1489.
6. Bautista-Lopez, N., B.J. Ward, E. Mills, et al. 2000. Development and durability of measles antigen-specific lymphoproliferative response after MMR vaccination. Vaccine 18:1393.
7. Billeter, M.A., K. Baczko, A. Schmid, et al. 1984. Cloning of DNA corresponding to four different measles virus genomic regions. Virology 132:147.
8. Burnet, F. 1968. Measles as an index of immunological function. Lancet 2:610.
9. CDC. 1998. Progress toward global measles control and regional elimination, 1990-1997. MMWR 47:1049.
10. CDC. 1999. Global measles control and regional elimination, 1998-1999. MMWR 48:1124.
11. CDC. 2003. Update: global measles control and mortality reduction-worldwide, 1991-2001. MMWR 52:471.
12. Clements, C.J., and F.T. Cutts. 1995. The epidemiology of measles: thirty years of vaccination. Curr. Top. Microbiol. Immunol. 191:13.
13. Cutts, F.T., and L.E. Markowitz. 1994. Successes and failures in measles control. J. Infect. Dis. 170:S32.
14. El Kasmi, K.C., and C.P. Muller. 2001. New strategies for closing the gap of measles susceptibility in infants: towards vaccines compatible with current vaccination schedules. Vaccine 19:2238.
15. Gans, H., A. Arvin, J. Galinus, et al. 1998. Deficiency of the humoral immune response to measles vaccine in infants immunized at age 6 months. JAMA 280:527.
16. Gans, H., Y. Maldonado, L. Yasukawa, et al. 1999. Interleukin 12, interferon-γ and T cell proliferation to measles in immunized infants. J. Immunol. 162:5569.
17. Gans, H., L. Yasukawa, M. Rinki, et al. 2001. Immune responses to measles and mumps vaccination of infants at 6, 9, and 12 months. J. Infect. Dis. 184:817.
18. Griffin, D.E. 1995. Immune responses during measles virus infection. Curr. Top. Microbiol. Immunol. 191:117.
19. Hickman, C.J., A.S. Khan, P.A. Rota, et al. 1997. Use of synthetic peptides to identify measles nucleoprotein T-cell epitopes in vaccinated and naturally infected humans. Virology 235:386.
20. Hussey, G.D., E.A. Goddard, J. Hughes, et al. 1996. The effect of Edmonston-Zagreb and Schwarz measles vaccines on immune response in infants. J. Infect. Dis. 173:1320.
21. Kumar, M.L., C.E. Johnson, L.W. Chui, et al. 1998. Immune response to measles vaccine in 6-month-old infants of measles seronegative mothers [erratum appears in Vaccine 1999;17:2206], Vaccine 16:2047.
22. Kumar, M.L., C.E. Johnson, L.W. Chui, et al. 1998. Immune response to measles vaccine in 6-month-old infants of measles seronegative mothers [erratum appears in Vaccine 1999;17:2206], Vaccine 16:2047.
23. Maldonado, Y.A., E.C. Lawrence, R. DeHovitz, et al. 1995. Early loss of passive measles antibody in infants of mothers with vaccine-induced immunity, Pediatrics 96:447.
24. Markowitz, L.E., P. Albrecht, W.A. Orenstein, et al. 1992. Persistence of measles antibody after revaccination, J. Infect. Dis. 166:205.
25. Markowitz, L.E., S.R. Preblud, P.E. Fine, et al. 1990. Duration of live measles vaccine-induced immunity. Pediatr. Infect. Dis. J. 9:101.
26. Pabst, H.F., D.W. Spady, M.M. Carson, et al. 1999. Cell-mediated and antibody immune responses to AIK-C and Connaught monovalent measles vaccine given to 6-month-old infants. Vaccine 17:1910.
27. Putz, M.M., F.B. Bouche, R.L. de Swart, et al. 2003. Experimental vaccines against measles in a world of changing epidemiology. Int. J. Parasitol. 33:525.
28. Putz, M.M., and C.P. Muller. 2003. The rationale of a peptide-conjugate vaccine against measles. Vaccine 21:663.
29. Reilly, C., J. Stokes, E. Buynak, et al. 1961. Living attenuated measles-virus vaccine in early infancy. N. Engl. J. Med. 265:165.
30. Rozenblatt, S., O. Eizenberg, R. Ben-Levy, M. R. Mardiney Jr., et al. 1985. Sequence homology within the morbilliviruses. J. Virol. 53:684.
31. Ruckdeschel, J., K. Graziano, and M.M. Jr. 1975. Additional evidence that the cell-associated immune system is the primary host defense against measles (rubeola). Cell. Immunol. 17:11.
32. Shelton, J.D., J.E. Jacobson, W.A. Orenstein, et al. 1978. Measles vaccine efficacy: influence of age at vaccination vs. duration of time since vaccination. Pediatrics 62:961.
33. Siegrist, C., C. Barrios, X. Martinex, et al. 1998. Influence of maternal antibodies on vaccine responses: inhibition of antibody but not T cell responses allows successful early prime-boost strategies in mice. Eur. J. Immunol. 28:4138.
34. Smedman, L., A. Joki, A. Jose da Silva, et al. 1994, Immunosuppression after measles vaccination, Acta Paediatr. 83:164.
35. Stetler, H.C., W.A. Orenstein, R.H. Bernier, et al. 1986. Impact of revaccinating children who initially received measles vaccine before 10 months of age. Pediatrics 77:471.
36. Stokes, J., C. Reilly, M. Hilleman, et al. 1960. Use of living attenuated measles-virus vaccine in early infancy. N. Engl. J. Med. 263:230.
37. + T cell frequencies by flow cytometry: evidence for a novel, antigen-specific homeostatic mechanism in HIV-associated immunodeficiency. J. Clin. Invest. 99:1739.
38. Yeager, A.S., J.H. Davis, L.A. Ross, et al. 1977. Measles immunization. Successes and failures. JAMA 237:347.